A platform for pandemic preparedness
AdJane is a vaccine platform company supporting long-term pandemic preparedness and global health, including applications in antimicrobial resistance.
About us
AdJane is a vaccine platform company supporting long-term pandemic preparedness and global health, including applications in antimicrobial resistance.
Our platform is based on native Outer Membrane Vesicles (nOMVs) derived from Neisseria meningitidis and provides intrinsic innate immune activation. This enables its use as a self-adjuvanting platform for antigen presentation.
The platform has been clinically evaluated in a mucosal respiratory virus vaccine setting, where a favorable safety profile was observed. It supports both intramuscular and mucosal vaccine development, enabling flexibility across different transmission routes and public-health objectives.
Pandemic preparedness is increasingly recognized as a structural, long-term challenge, rather than a sequence of isolated emergency responses. While rapid vaccine development has proven possible in acute situations, sustaining readiness over time requires technologies that can be maintained, adapted and redeployed.
Preparedness therefore depends on platforms that can be preserved, adapted and reused across scenarios, rather than rebuilt for each emerging threat.
AdJane’s platform provides a robust and repeatable foundation for vaccine development across multiple disease contexts, supporting both rapid response and long-term preparedness strategies.
Platform
Designed for adaptability and integration
Our platform is based on native Outer Membrane Vesicles (nOMVs) derived from Neisseria meningitidis that provide intrinsic innate immune activation. The platform supports flexible multivalent vaccine design: antigens can be displayed on the nOMVs and/or co-administered with them as an adjuvant, enabling tailored immune strategies across multiple routes of administration. This design allows vaccine approaches to be adapted to different
transmission dynamics and public-health needs, while maintaining a consistent underlying technology.
Rather than focusing on a single indication, the AdJane platform incorporates foundational capabilities that can be applied, adapted and integrated across different vaccine strategies and development contexts. This approach supports continuity across programs while allowing components to be adjusted independently as requirements evolve.
The platform can be applied across:
- Viral and bacterial pathogens
- Mono- and multivalent vaccine concepts
- Mucosal and intramuscular routes of administration